1.Lyu Z, Feng X, Li N, Zhao W, Wei L, Chen Y, Yang W, Ma H, Yao B, Zhang K et al: Human papillomavirus in semen and the risk for male infertility: a systematic review and meta-analysis. BMC infectious diseases 2017, 17(1):714.
2.World Health Organization (WHO): Human papillomavirus (HPV) and cervical cancer. [https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer] Accessed 28 March 2019.
3.Braaten KP, Laufer MR: Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. Rev Obstet Gynecol 2008, 1(1):2–10.
4.Kraut AA, Schink T, Schulze-Rath R, Mikolajczyk RT, Garbe E: Incidence of anogenital warts in Germany: a population-based cohort study. BMC infectious diseases 2010, 10:360.
5.Kodner CM, Nasraty S: Management of genital warts. Am Fam Physician 2004, 70(12):2335–2342.
6.Patel H, Wagner M, Singhal P, Kothari S: Systematic review of the incidence and prevalence of genital warts. BMC infectious diseases 2013, 13:39–39.
7.Thöne K, Horn J, Mikolajczyk R: Evaluation of vaccination herd immunity effects for anogenital warts in a low coverage setting with human papillomavirus vaccine-an interrupted time series analysis from 2005 to 2010 using health insurance data. BMC infectious diseases 2017, 17(1):564–564.
8.Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV: The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002, 55(4):244–265.
9.Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A: Global cancer statistics, 2012. CA Cancer J Clin 2015, 65(2):87–108.
10.Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregister in Deutschland: Krebs in Deutschland für 2013/2014. Berlin: Robert Koch-Institut; 2017.
11.Hartwig S, Baldauf J-J, Dominiak-Felden G, Simondon F, Alemany L, de Sanjosé S, Castellsagué X: Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines. Papillomavirus Research 2015, 1:90–100.
12.Reuschenbach M, Roos J, Panayotopoulos D, Baldus SE, Schnürch H-G, Berger A, Petry KU, Dürst M, Seiz M, von Knebel Doeberitz M et al: Characterization of Squamous Cell Cancers of the Vulvar Anterior Fourchette by Human Papillomavirus, p16INK4a, and p53. Journal of Lower Genital Tract Disease 2013, 17(3):289–297.
13.European Medicines Agency: HPV vaccines: EMA confirms evidence does not support that they cause CRPS or POTS. [https://www.ema.europa.eu/en/documents/referral/hpv-vaccines-article–20-procedure-ema-confirms-evidence-does-not-support-they-cause-crps-pots_en.pdf] Accessed 15 April 2019.
14.Robert Koch-Institut: Impfquoten bei der Schuleingangsuntersuchung in Deutschland 2014. Epidemiologisches Bulletin, 2016, 16/2014:129–142.
15.Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, Moreira ED, Jr., Ngan Y, Petersen LK, Lazcano-Ponce E et al: A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. The New England journal of medicine 2015, 372(8):711–723.
16.Serrano B, Alemany L, Tous S, Bruni L, Clifford GM, Weiss T, Bosch FX, de Sanjose S: Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012, 7(1):38.
17.Wiese-Posselt M, Tertilt C, Zepp F: Vaccination recommendations for Germany. Dtsch Arztebl Int 2011, 108(45):771–780.
18.Robert Koch-Institut: Mitteilung der Ständigen Impfkommission (STIKO) am Robert Koch-Institut: Impfung gegen humane Papillomaviren (HPV) für Mädchen von 12 bis 17 Jahren—Empfehlung und Begründung. Epidemiologisches Bulletin 2007, 12/2007:97–106.
19.Takla A, Wiese-Posselt M, Harder T, Meerpohl JJ, Röbl-Mathieu M, Terhardt M, van der Sande M, Wichmann O, Zepp F, Klug SJ: Background paper for the recommendation of HPV vaccination for boys in Germany. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 2018, 61(9):1170–1186.
20.Robert Koch-Institut: Wissenschaftliche Begründung für die Empfehlung der HPV-Impfung für Jungen im Alter von 9 bis 14 Jahren. Epidemiologisches Bulletin, 2018, 26/2018:233–254.
21.Hense S, Hillebrand K, Horn J, Mikolajczyk R, Schulze-Rath R, Garbe E: HPV vaccine uptake after introduction of the vaccine in Germany: an analysis of administrative data. Hum Vaccin Immunother 2014, 10(6):1729–1733.
22.Robert Koch-Institut: Aktuelles aus der KV-Impfsurveillance—Impfquoten ausgewählter Schutzimpfungen in Deutschland. Epidemiologisches Bulletin 2018, 1/2018.
23.Robert Koch-Institut: Vaccination againsthuman papillomavirus (HPV) in girls. Fact sheet on KiGGS Wave 1: German Health Interview and Examination Survey for Children and Adolescents—First follow-up interview 2009−2012. 2014.
24.Geyer S, Jaunzeme J, Hillemanns P: Cervical cancer screening in Germany: group-specific participation rates in the state of Niedersachsen (Lower Saxony). A study with health insurance data. Archives of gynecology and obstetrics 2015, 291(3):623–629.
25.Andersohn F, Walker J: Characteristics and external validity of the German Health Risk Institute (HRI) Database. Pharmacoepidemiology and drug safety 2016, 25(1):106–109.
26.Agresti A, Coull BA: Approximate Is Better than “Exact” for Interval Estimation of Binomial Proportions. The American Statistician 1998, 52(2):119–126.
27.Delere Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A, Wichmann O, Kaufmann AM: Human Papillomavirus prevalence and probable first effects of vaccination in 20 to 25 year-old women in Germany: a population-based cross-sectional study via home-based self-sampling. BMC infectious diseases 2014, 14:87.
28.National HPV Vaccination Program Register: National (Australia) HPV 3 dose vaccination coverage for females turning 15 years of age in 2015. [http://www.hpvregister.org.au/site/DefaultSite/filesystem/documents/Coverage-Data/2018/Coverage%20by%20dose%202015%20-%20females.pdf] Accessed 13 May 2019.
29.Mikolajczyk RT, Kraut AA, Horn J, Schulze-Rath R, Garbe E: Changes in incidence of anogenital warts diagnoses after the introduction of human papillomavirus vaccination in Germany-an ecologic study. Sexually transmitted diseases 2013, 40(1):28–31.
30.Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Schulze-Rath R, Iftner T: Prevalence of low-risk HPV types and genital warts in women born 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC infectious diseases 2012, 12:367.
31.Petry KU, Luyten A, Justus A, Iftner A, Strehlke S, Reinecke-Luthge A, Grunwald E, Schulze-Rath R, Iftner T: Prevalence of high-risk HPV types and associated genital diseases in women born in 1988/89 or 1983/84 - results of WOLVES, a population-based epidemiological study in Wolfsburg, Germany. BMC infectious diseases 2013, 13:135.
32.Chow EPF, Read TRH, Wigan R, Donovan B, Chen MY, Bradshaw CS, Fairley CK: Ongoing decline in genital warts among young heterosexuals 7 years after the Australian human papillomavirus (HPV) vaccination programme. Sexually Transmitted Infections 2015, 91(3):214–219.
33.Zentrum für Krebsregisterdaten (ZfKD): Datenbankabfrage. [https://www.krebsdaten.de/Krebs/SiteGlobals/Forms/Datenbankabfrage/datenbankabfrage_stufe2_form.html] Accessed 15 May 2019.
34.Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D: Epidemiology of vulvar and vaginal cancer in Germany. Archives of gynecology and obstetrics 2011, 284(1):169–174.
35.Garland SM, Kjaer SK, Munoz N, Block SL, Brown DR, DiNubile MJ, Lindsay BR, Kuter BJ, Perez G, Dominiak-Felden G et al: Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2016, 63(4):519–527.
36.Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R: Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Advances in therapy 2015, 32(1):10–30.
37.Deutsches Institut für Medizinische Dokumentation und Information (DIMDI): ICD–10-GM - Versionsverlauf und Bekanntmachungen. [https://www.dimdi.de/dynamic/de/klassifikationen/icd/icd–10-gm/historie/versionsverlauf/] Accessed 15 April 2019.
38.GKV Spitzenverband: Fokus: Asylsuchende/ Flüchtlinge. [https://www.gkv-spitzenverband.de/presse/themen/fluechtlinge_asylbewerber/fluechtlinge.jsp] Accessed 22 Nov 2019.